NCT00545701View on ClinicalTrials.gov

Immunogenicity and Safety of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

June 30, 2008

Study Completion Date

September 30, 2008

Conditions
InfluenzaOrthomyxoviridae Infections
Interventions
BIOLOGICAL

A/H5N1 inactivated, split-virion influenza virus

0.5 mL, Intramuscular

Trial Locations (2)

Unknown

Adelaide

Queensland

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT00545701 - Immunogenicity and Safety of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Adults | Biotech Hunter | Biotech Hunter